



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 892 048 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
20.01.1999 Bulletin 1999/03(51) Int. Cl.⁶: C12N 15/12, C12N 15/11,
C07K 14/47, C12N 15/85,
C12N 5/10, A01K 67/027,
G01N 33/50, A61K 38/17,
A61K 48/00, C12Q 1/68,
C12P 21/08

(21) Application number: 98113003.2

(22) Date of filing: 13.07.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SEDesignated Extension States:
AL LT LV MK RO SI(30) Priority: 14.07.1997 US 52402 P
01.08.1997 US 54491 P
18.08.1997 US 56338 P(71) Applicant: UNIVERSITY OF OTTAWA
Ottawa, Ontario K1N 6N5 (CA)(72) Inventors:
• Korneluk, Robert
Ottawa Ontario K1G 2L8 (CA)

- Tamai, Katsuyuki
Nagano Prefecture (JP)
- Liston, Peter
Ottawa, Ontario K1S 2H2 (CA)
- Mackenzie, Alexander E.
Ottawa, Ontario K1M 1A3 (CA)
- Baird, Stephen
Ottawa Ontario K1Y 0S5 (CA)

(74) Representative:
Vossius, Volker, Dr. et al
Dr. Volker Vossius,
Patentanwaltskanzlei - Rechtsanwaltskanzlei,
Holbeinstrasse 5
81679 München (DE)

(54) XAF genes and polypeptides and their use for modulating apoptosis

(57) The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis.

EP 0 892 048 A2